Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Sold by American Century Companies Inc.

American Century Companies Inc. cut its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 8.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 848,630 shares of the company's stock after selling 83,020 shares during the quarter. American Century Companies Inc. owned approximately 1.71% of Mineralys Therapeutics worth $10,447,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. AlphaQuest LLC grew its stake in shares of Mineralys Therapeutics by 2,637.8% during the fourth quarter. AlphaQuest LLC now owns 15,222 shares of the company's stock worth $187,000 after purchasing an additional 14,666 shares in the last quarter. Candriam S.C.A. purchased a new stake in Mineralys Therapeutics during the 4th quarter worth about $3,758,000. Proficio Capital Partners LLC acquired a new position in shares of Mineralys Therapeutics during the 4th quarter worth about $285,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Mineralys Therapeutics by 0.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 214,906 shares of the company's stock valued at $2,645,000 after acquiring an additional 1,307 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of Mineralys Therapeutics by 2.7% during the 4th quarter. Bank of New York Mellon Corp now owns 65,318 shares of the company's stock worth $804,000 after acquiring an additional 1,711 shares in the last quarter. 84.46% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analyst Weigh In

MLYS has been the subject of a number of research analyst reports. Guggenheim reaffirmed a "buy" rating on shares of Mineralys Therapeutics in a report on Monday, February 24th. HC Wainwright upped their target price on shares of Mineralys Therapeutics from $30.00 to $42.00 and gave the company a "buy" rating in a report on Wednesday, April 2nd. Finally, The Goldman Sachs Group dropped their target price on shares of Mineralys Therapeutics from $28.00 to $24.00 and set a "buy" rating on the stock in a research report on Thursday, February 13th.

Mineralys Therapeutics Trading Down 2.8 %

Shares of NASDAQ MLYS traded down $0.35 during trading hours on Monday, reaching $12.05. The stock had a trading volume of 1,270,586 shares, compared to its average volume of 387,417. The firm has a 50-day moving average of $11.94 and a 200-day moving average of $12.28. The firm has a market cap of $756.56 million, a price-to-earnings ratio of -3.31 and a beta of -0.39. Mineralys Therapeutics, Inc. has a fifty-two week low of $8.24 and a fifty-two week high of $18.38.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.98) earnings per share for the quarter, beating analysts' consensus estimates of ($1.00) by $0.02. On average, equities analysts predict that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.

Insider Activity at Mineralys Therapeutics

In related news, major shareholder Samsara Biocapital Gp, Llc purchased 600,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The shares were purchased at an average price of $13.50 per share, for a total transaction of $8,100,000.00. Following the transaction, the insider now directly owns 5,674,916 shares of the company's stock, valued at approximately $76,611,366. The trade was a 11.82 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Jon Congleton sold 18,333 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $9.06, for a total value of $166,096.98. Following the sale, the chief executive officer now directly owns 877,608 shares of the company's stock, valued at $7,951,128.48. The trade was a 2.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 84,861 shares of company stock worth $1,142,937 in the last 90 days. 33.24% of the stock is owned by insiders.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.